Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Generic Paxil CR Will Launch By October 2008 Under GSK/Mylan Settlement

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Mylan gains rights to market extended-release paroxetine in 12.5 mg, 25 mg and 37.5 mg doses.

You may also be interested in...



Mylan Launches Generic Paxil CR

Launch includes 180-day exclusivity for 12.5 mg and 25 mg paroxetine tablets, and follows patent settlement with GSK last year.

Mylan Launches Generic Paxil CR

Launch includes 180-day exclusivity for 12.5 mg and 25 mg paroxetine tablets, and follows patent settlement with GSK last year.

Generic Keppra Set For Launch In November 2008 After UCB Settles

Mylan could launch generic versions of the antiepileptic Nov. 1, 2008, two months ahead of anticipated exclusivity expiry of levetiracetam.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest News

Arnold Ventures: How A Philanthropy Helped Tip The Scales In US Drug Pricing Debate

It’s The Overall Survival, Sponsors! Ovarian Cancer Indications Withdrawn For Three PARP Inhibitors

Cell, Gene Therapy A No Entry Zone? EU Group Seeks Clarification Over China Regs

FDA Allowed Release Of Moderna COVID Booster While Still Mulling Plant Inspection Findings

See All
UsernamePublicRestriction

Register

PS065245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By